QSAM — Qsam Biosciences Share Price
0.000.00%
Last trade - 00:00- $35.56m
- $34.18m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 52.89 | ||
| Price to Tang. Book | 52.89 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -586.68% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
QSAM Biosciences, Inc. is developing nuclear medicines for the treatment of cancer and related diseases. The Company’s technology, CycloSam (Samarium-153 DOTMP), is a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group, LLC. Iso Therapeutics Group LLC also developed a commercial radiopharmaceutical on the market, Quadramet (Samarium-153 EDTMP), which is indicated for pain palliation. CycloSam consists of a combination of the radioactive isotope Samarium-153 with a chelating agent, DOTMP (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetramethylenephosphonic acid). Its combination delivers a radioactive dose to sites of bone mineral turnover, such as bone cancers and tumors. CycloSam has a physical half-life of approximately 46 hours and emits both medium-energy beta particles, which produce the therapeutic effect and gamma photons that make it possible to take images of the skeleton and locate and characterize the size and nature of tumors.
Directors
- C. Richard Piazza CHM (73)
- Douglas Baum CEO (54)
- Adam King CFO (36)
- Christopher Nelson GCN (51)
- Charles Link IND (61)
- Joel Mayersohn IND (62)
- Adriann Sax IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 26th, 2004
- Public Since
- August 25th, 2011
- No. of Shareholders
- 342
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 4,445,469
- Address
- 9442 CAPITAL OF TEXAS HWY N, AUSTIN, 78759
- Web
- https://qsambio.com/
- Phone
- +1 5123434558
- Contact
- Jason Nelson
- Auditors
- D. Brooks and Associates CPAs, P.A.
Upcoming Events for QSAM
Q2 2024 Qsam Biosciences Inc Earnings Release
Similar to QSAM
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Qsam Biosciences share price?
As of Today at 19:17 UTC, shares in Qsam Biosciences are trading at $8.00. This share price information is delayed by 15 minutes.
How has the Qsam Biosciences share price performed this year?
Shares in Qsam Biosciences last closed at $8.00 and the price had moved by +33.33% over the past 365 days. In terms of relative price strength the Qsam Biosciences share price has outperformed the S&P500 Index by +15.16% over the past year.
What are the analyst and broker recommendations for Qsam Biosciences?
There is no consensus recommendation for this security.
Find out moreWhat is the Qsam Biosciences dividend yield?
Qsam Biosciences does not currently pay a dividend.
Does Qsam Biosciences pay a dividend?
Qsam Biosciences does not currently pay a dividend.
When does Qsam Biosciences next pay dividends?
Qsam Biosciences does not currently pay a dividend.
How do I buy Qsam Biosciences shares?
To buy shares in Qsam Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Qsam Biosciences?
As of the previous close price of $8.00, shares in Qsam Biosciences had a market capitalisation of $35.56m.
Where are Qsam Biosciences shares listed?
Here are the trading details for Qsam Biosciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: QSAM
What kind of share is Qsam Biosciences?
Based on an overall assessment of its quality, value and momentum Qsam Biosciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Qsam Biosciences share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Qsam Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Qsam Biosciences. Over the past six months, its share price has outperformed the S&P500 Index by +39.06%.
As of the last closing price of $8.00, shares in Qsam Biosciences were trading +38.75% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Qsam Biosciences PE Ratio?
The Qsam Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Qsam Biosciences?
Qsam Biosciences' management team is headed by:
- C. Richard Piazza - CHM
- Douglas Baum - CEO
- Adam King - CFO
- Christopher Nelson - GCN
- Charles Link - IND
- Joel Mayersohn - IND
- Adriann Sax - IND